Impact of New ADHD Treatments - Free Essay Sample

Introduction

ADHD is a neurodevelopmental disorder usually diagnosed first in the childhood stage, which in most cases, progresses into adulthood. Individuals who have ADHD find it hard to control their impulsive behaviors and have difficulties paying attention. The Food and Drug Administration (FDA) approved two new ADHD medications: Cotempla XR-ODT and Mydayis. In this essay, the impacts of the latest ADHD treatment are reviewed and presented. The benefits of administering ADHD treatment discussed below are reduced troublesome symptoms, enhanced academic performance, and guaranteed health safety. The side effects discussed are sleep problems, delayed growth, rebound, and Dysphoria.

Is your time best spent reading someone else’s essay? Get a 100% original essay FROM A CERTIFIED WRITER!

Save 25%

Benefits of the New ADHD Treatment

ADHD disorder is associated with troublesome symptoms such as difficulty in concentration and controlling impulsive behaviors. The new ADHD treatment reduces the levels of troubling symptoms in an individual. Administering the ADHD treatment, therefore, renders the individual less capricious. Reduction in the person's hyperactive nature improves the levels of focus. That is so as he becomes less distractible (Dallos et al., 2017). That, in turn, influences the better performance of an individual in the normal society setup. Taking and interpreting instructions and guidelines is also enhanced due to reduced troublesome symptoms. It is, however, essential to note that the medication does not address any learned norm.

The new ADHD treatment enhances good academic performance, which is influenced by the learner's concentration levels. ADHD limits concentration and paying attention as expected. Improved concentration is influenced by administering the new ADHD medication, ensuring mastery of academic concepts. Attaining good grades in the school oral, practical, and written tests justifies the new ADHD medication (Hauck et al., 2017). that results in the Elevation of the academic position and status due to improved academic performance. That changes the social status due to the increased number of learned individuals. ADHD treatment, therefore, fully exploits the educational potential of people.

The new ADHD treatment does not pose health-related risks. The treatment is not only practical, but its stimulant nature guarantees health safety. That is so because stimulant medications are short-acting; therefore, they do not remain in the body for very long (Rasmussen et al., 2019). when the child wakes up, the medication is cleared from the body system regardless of the frequency. The drug stops taking effect immediately; the child stops using them. That translates to preventing side effects such as loss of sleep and appetite.

Side Effects of the New ADHD Treatment

The new ADHD treatment administration may cause sleeping problems for the person in question. Individuals prescribed by professionals to take a short-acting formula majorly face sleeping difficulties. The procedure entails taking the second or the third dose late in the day, and by bedtime, it has not worn off (Dallos et al., 2017). That occurs in a scenario whereby the patient is taking medicine that lasts 12 to 14 hours. The active medication state makes the person awake into the wee hours. In turn, the body does not have the required rest and may develop other health-related complications.

ADHD treatment may lead to delayed growth in the kid administered in to. A stimulant nature characterizes the new ADHD treatment. Boys particularly tend to grow more slowly as an effect of taking stimulant medication. However, by the second and third years, they catch up and have progressive growth (Hauck et al., 2017). also, boys who took medication breaks during the weekends and summer did not face delayed development in the first year. Due to hormonal variations, girls do not meet stipulated side effects.

Rebound side effects have also occurred when the medication wears off. The kids become very aggressive and irritable, as reported by most parents. That is due to the medicine's tendency to leave receptors in the brain very fast (Dallos et al., 2017). It is advisable to give the child a smaller dose half an hour before rebound happens to help the child ease off the medication gradually. Sometimes rebound occurs due to the drug's high dosage or does not work in the child. It is advisable to consult a professional to prescribe a different medication compatible with the child.

Dysphoria is another side effect of the new ADHD medication in children, which induces a total lack of emotional expression or an overly focused state. That makes a child an automaton as the child moves from one task to another without any personal expression. Dysphoria is a dramatic change occurring in a child (Rasmussen et al., 2019). That is majorly due to the high dosage of the ADHD medication. In a scenario where Dysphoria occurs in a child, the parent should consult with the health care team.

Conclusion

ADHD disorder, when diagnosed, should be addressed with immediate effect by consulting a professional. The new treatment introduced incorporates Cotempla XR-ODT and Mydayis medications. The benefits of administering the medicines as discussed reduce troublesome symptoms such as sleeping and concentration difficulties. The drug also enhances academic performance as a result of addressing concentration issues. The new ADHD medication guarantees health safety due to its stimulant nature. Stimulants do not remain in the body for long. Therefore the side effects are only experienced when the drug is active in the body. The side effects discussed include loss of sleep, which occurs when the medicine is functional in the body. That mainly happens in patients under the short-acting formula. Another side effect majorly experienced in boys is delayed growth. A rebound side effect occurs after the medication leaves the body. Dysphoria is noticed, especially under high dosage. A recommendation to consult a health practitioner in case of side effects ensure opting for the right action.

References

Dallos, G., Miklósi, M., Keresztény, & Balázs, J. (2017). Self-and parent-rated quality of life of a treatment naïve sample of children With ADHD: the impact of age, gender, type of ADHD, and comorbid psychiatric conditions according to both a categorical and a dimensional approach. Journal of Attention Disorders, 21(9), 721-730. https://journals.sagepub.com/doi/abs/10.1177/1087054714542003

Hauck, T. S., Lau, C., Wing, L. L. F., Kurdyak, P., & Tu, K. (2017). ADHD treatment in primary care: demographic factors, medication trends, and treatment predictors. The Canadian Journal of Psychiatry, 62(6), 393-402. https://journals.sagepub.com/doi/abs/10.1177/0706743716689055

Rasmussen, P. D., Bilenberg, N., & Storebø, O. J. (2019). Attachment representations in mothers and their children diagnosed with ADHD: Distribution, transmission, and impact on treatment outcome. Journal of Child and Family Studies, 28(4), 1018-1028. https://link.springer.com/article/10.1007/s10826-019-01344-5